ADGM Adagio Medical Holdings, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ADGM matters now
Adagio Medical Holdings, Inc. (ADGM) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.57 with +0.69% on the session and $8.7M in market capitalization; recent performance reads 1-month -18.56% and YTD -34.62%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-7.0M, and EPS of $-0.31. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -150.7%.
The latest indexable market news headline is "Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.00; recent insider activity includes Usen Todd filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.64
P/S
0.00
EV/EBITDA
-1.17
DCF Value
$-0.25
FCF Yield
-150.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-382.5%
ROA
-62.0%
ROIC
-63.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-7.0M | $-0.31 |
| Q4 2025 | $0.00 | $-3.3M | $-0.16 |
| FY 2025 | $0.00 | $-25.1M | $-1.51 |
| Q3 2025 | $0.00 | $-10.1M | $-0.66 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$3.00 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
-0.19
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.